Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Q2 2026 Earnings Presentation
30 slides from Cantargia Ab's earnings presentation, Aug 19, 2026
Slide 1: Blocking the RIGHT signals to reduce disease severity
Blocking the RIGHT signals to reduce disease severity Q2 2026 PRESENTATON August 19, 2026 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Q2 Report 2026
Q2 REPORT 2026 Hilde Steineger Patrik Renblad Chief Executive Officer Chief Financial Officer
Slide 4: Significant Events in the Quarter
Significant Events in the Quarter Rights Issue secures Combination Study with nadunolimab and daraxonrasib in PDAC • With the main purpose of funding key strategic clinical development activities for nadunolimab, primarily a combination study with the RAS inhibitor daraxonrasib in pancreatic ductal
Slide 5: Our IL1RAP-Focused Pipeline
Our IL1RAP-Focused Pipeline Asset Target Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Partner Oncology PDAC + Daraxonrasib - Phase 1b Planned Nadunolimab IL1RAP MDS/AML1 Investigator-Initiated Trial CANxx Unique IL1RAP platform2 Autoimmune CAN14 IL1RAP BsAb3 Autoimmune diseases CAN10 IL1
Slide 6: Cantargia – Oncology
CANTARGIA – ONCOLOGY
Slide 7: Pancreatic Ductal Adenocarcinoma – PDAC
PANCREATIC DUCTAL ADENOCARCINOMA – PDAC
Slide 8: Preparing for Study with nadunolimab and daraxonrasib in 2L metastatic PDAC
Preparing for Study with nadunolimab and daraxonrasib in 2L metastatic PDAC An open-label Phase 1b trial designed to assess safety and tolerability of nadunolimab combined with daraxonrasib in metastatic PDAC patients who had previously progressed on 1L SoC Survival Follow Up Study population: Nadun
Slide 9: Future of PDAC Management – Two Targetable Pathways
Future of PDAC Management – Two Targetable Pathways with Strong Combination Potential → KRAS fuels IL-1 dependent tumor inflammation → Autocrine IL-1 activates IL1RAP and triggers tumor cell intrinsic IRAK-dependent signaling → IL-1 signaling shapes the TME by activating IL1RAP on myeloid cells and
Slide 10: High IL1RAP Expression Is Linked to Poor Outcome in KRAS mutated Pancreatic Tumors
High IL1RAP Expression Is Linked to Poor Outcome in Patients with KRAS mutated Pancreatic Tumors OS from diagnosis - KYT OS from diagnosis – KYT w KRAS mutation → High IL1RAP RNA expression in PDAC tumors correlate with poor survival → IL1RAP levels strongly influence survival in allcomers as well a
Slide 11: Nadunolimab and daraxonrasib have complementary MoA
Nadunolimab and daraxonrasib have complementary MoA nadunolimab nadunolimab nadunolimab daraxonrasib 11 chemotherapy
Slide 12: Myeloid Malignancies – MDS & AML
MYELOID MALIGNANCIES – MDS & AML
Slide 13: IIT at MD Anderson: Ph1b/2a Study in MDS/AML
IIT at MD Anderson: Ph1b/2a Study in MDS/AML Principal Investigator: Gautam Borthakur, MD, MD Anderson Cancer Center Grant support: U.S. Department of Defense (DOD) Study start 2025 Arm 1 HR-MDS (n=20): Cycle 1 Cycle 2-24 • Intermediate/high/very high risk MDS* • Untreated or up to 2 Treatment prior
Slide 14: Encouraging Leukemia Data Reinforce IL1RAP as a High-Risk Target
Encouraging Leukemia Data Reinforce IL1RAP as a High-Risk Target → IL1RAP is overexpressed in leukemic disease and linked to adverse inflammatory and signaling profiles p=2.2 x 10-7 → In AML, higher IL1RAP expression has been associated with poorer outcomes in independent clinical studies → Supports
Slide 15: MDS and AML – IL1RAP at the Center of Disease
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) – IL1RAP at the Center of Disease MDS: • Originates from IL1RAP+ leukemia stem cells (LSC) in the bone marrow (BM) • LSC produces immature, non-functional, blast cells, in MDS <20% of BM • Divided into low, intermediate and high risk •
Slide 16: IL1RAP Expression increases with Disease Aggressiveness
IL1RAP Expression increases with Disease Aggressiveness Relative IL1RAP expression across myeloid disease states Conceptual scale based on published flow-cytometry observations Key message Healthy hematopoietic stem cells (HSCs) Relative expression show very low or undetectable IL1RAP IL1RAP-high ex
Slide 17: Nadunolimab in MDS and AML – Targeting the Root Cause of the Disease
Nadunolimab in MDS and AML – Targeting the Root Cause of the Disease → LSCs escape current chemotherapeutic treatment strategies, thereby providing a reservoir for disease relapse → Strong medical need for targeting LSCs with specificity → IL1RAP is expressed in AML and high-risk MDS → IL1RAP is exp
Slide 18: High-risk MDS comprises ~35% of all new MDS cases
High-risk (HR) Myelodysplastic Syndrome (MDS) comprises ~35% of all new MDS cases Global Prevalence – Treatment (HMA) Unmet need Value MDS* • ~400.000 MDS patients Stem Cell transplantation Delay leukemic (AML) Backbone HMA reatment: • (HSCT) - the only • HR patients: ~ 35% – Vidaza (5-azacitidine)
Slide 19: CAN14 and CANXX Next generation IL1RAP therapeutics
CAN14 and CANXX Next generation IL1RAP therapeutics CANXX is a program for new therapeutics and reagents comprising unique antibodies, reagents and knowledge around IL1RAP as a drug target. CAN10 was the first program originating from the CANXX platform, CAN14 is the second that adds new features to
Slide 20: CANxx – a Generator for New Drugs and Reagents
CANxx – a Generator for New Drugs and Reagents • Knowledge of IL1RAP and its role in disease • A library of ~500 anti-IL1RAP antibodies and clones within the CANxx platform • CANxx antibodies bind to different domains of IL1RAP and have different functional properties CANXX – A COMPREHENSIVE SOURCE
Slide 21: Next-Generation IL1RAP Therapeutics
Next-Generation IL1RAP Therapeutics IL1RAP blockade is a potent way to block inflammation in preclinical and translational ex vivo models Bispecific mAbs Add new functionalities to IL1RAP blockade for improved efficacy and is tailored for specific diseases IL1RAP is expressed in a large number of so
Slide 22: Financial Results
FINANCIAL RESULTS
Slide 23: Summary of Second Quarter Profit & Loss
Summary of Second Quarter Profit & Loss MSEK Quarter 2 2026 0.1 -32.8 -35.9 -35.8 3.0 Revenues Operating Expenses Operating Results Net Financial Items Loss for the Period Earnings per share: -0.13 SEK 23
Slide 24: Summary of Profit & Loss for the First Six Months
Summary of Profit & Loss for the First Six Months MSEK First Six Months of 2026 0.6 -65.8 -73.3 -72.7 6.9 Revenues Operating Expenses Operating Result Net Financial Items Profit for the Period Earnings per share: -0.26 SEK 24
Slide 25: Operating Expenses in Q2 and First Six Months of 2026
Operating Expenses in Q2 and First Six Months of 2026 MSEK -9% 39.5 -13% 35.9 84.5 73.3 R&D 23.5 34.7 R&D 75.4 54.5 12.4 Admin&Other 4.8 Admin&Other 18.8 9.2 2025 Q2 2026 Q2 2025 H1 2026 H1 Q2 H1 25
Slide 26: Cash Flow and Cash Position
Cash Flow and Cash Position MSEK Operating Cash Flow 339 SEK -37m (Q2, 2025: SEK -44m) 282 258 Available funds (excluding rights issue proceeds & loan) 222 SEK 222m 339 (June 30, 2025: SEK 82m 282 246 210 82 Cash Runway Current available funds and the proceeds from the Rights Issue and the loan are
Slide 27: Key Financials & Investment Highlights
KEY FINANCIALS & INVESTMENT HIGHLIGHTS
Slide 28: Q2 2026 Summary
Q2 2026 Summary Financial strength and clinical momentum across the IL1RAP platform Financing event closed: Gross proceeds of 132 million SEK from a rights issue combined with a loan facility, earmarked for our key clinical priorities for nadunolimab PDAC: Phase 1b in preparation: Combination study
Slide 29: Questions!
QUESTIONS!
Slide 30: Thank you
(oantargia Thank you